Multidisciplinary group of TIL project.
In recent years, much progress has been made in the research of new treatments that use the abilities of our immune system to fight cancer. This is what is known as immunotherapy. There are various strategies within this area such as the development of advanced medicine (ATMP), therapy of which TIL cells (from the English tumor-infiltrating lymphocytes) is a clear example. now him Val d’Hebron Hospital The BBVA Foundation, in support of the Carlos III Institute of Health’s CAIMI program at the Val d’Hebron Institute of Oncology (VHIO), has reported the treatment of the first patient with its own cell therapy based on fully grown TIL cells. (ISCIII) and Banc de Sang i Teixits (BST) support. In this way, Val d’Hebron joins the world’s great hospitals that have been able to develop their own or academically advanced medical drugs (ATMPs) to administer to their patients.
It is these lymphocytes – immune cells found mainly in the blood – that enter tumors and which, once reactivated in the laboratory, are able to Identify and destroy tumor cells, Despite the fact that these lymphocytes are found in tumors, sometimes they are not very active or too few, which does not allow the tumor cells to be effectively eliminated, and, as a result, the tumor continues to grow. For this reason, it is necessary to reactivate and recover the functionality of lymphocytes and to expand them ex vivo in the laboratory and then to re-administer them to the patient.
team of elena grossoThe head of the VHIO Immunotherapy and Immunology Group, which has led the preclinical development of this therapy in support of the Comprehensive Immunotherapy and Immunology Program (CAIMI), promoted by the BBVA Foundation, has spent years researching
Antitumor responses produced naturally by T cells against mutations occurring in a variety of tumors, including endometrial cancer and other unresectable epithelial tumors. “Ultimately, it’s about creating an army of cells from the patient himself that helps us attack the tumor more effectively,” he explains. elena garaldaDirector of Cancer Molecular Therapy Research Unit (UITM) – CaixaResearch.
Due to the characteristics of the immune system, this treatment preparation is individualized for each patient, and at least one and a half months elapses from the time the tumor biopsy is obtained, until the TIL candidate patient is obtained. He does not receive his treatment. “It is time to be able to expand sufficiently in the laboratory to be able to administer them back to the patient. During this period, the patient continues with his usual treatment and when he stops responding Then we infect the pre-prepared TIL cells”, says Elena Garalda, who also states that the patient must undergo high-dose chemotherapy before vaccination. treatment that destroys the lymphocytes he already has, to make room for him new TIL cells,
An Innovative Cell Therapy Developed Entirely at VHIO
Once TIL cells are infected, Patients receiving different doses of interleukin-2 (IL-2), which helps these cells to expand and activate. This treatment produces a ‘high toxicity’ adverse effect in the short term, which is why it is administered in advanced medicine at the Hematology Unit (UTAH) of the Hospital Universitaire Val d’Hebron. It is an exclusive and pioneering entity in our country, allowing the administration of cell therapy treatments from a semi-intensive care and multidisciplinary approach, with professionals from different disciplines collaborating to provide the best quality care to these patients. Huh.
“This is the first step on the path that we know will be long because we know that Not all patients will respond to this therapyBut we hope that it can provide us with a new way to move forward. personalized cancer medicineR”, explains Alina Gros. able to do, in VHIO”, he says, highlighting that although there are Other Industry-Developed TIL AssaysIn this case it is an investigation from the academic field, a clear case of success.
There are also cases of patients treated with TIL therapy in Spain, with commercial products in clinical trials, but also in some cases with academic products, particularly in pediatric indications. Now Hospital Universitaire Val d’Hebron also joins this list of leading hospitals capable of offering this Experimental therapy for patients with solid tumors who have no therapeutic options, “It is a state-of-the-art therapy in immuno-oncology, requiring the participation of highly qualified professionals from various fields. A project of these specialties requires teamwork, coordination and the support of various units, one of its kind in Spain. leading, to come out
Forward”, comments Sylvia Martin Luesma, Clinical Senior Manager in Advanced Therapy at VHIO (Scientific Coordination Area) and Professor at San Pablo CEU University.
While it may include statements, data or notes from health institutions or professionals, the information contained in medical writing is edited and prepared by journalists. We advise the reader to consult a health professional on any health-related questions.